AZN - Why Is AstraZeneca Stock Trading Lower Today? | Benzinga
AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some analysts.
The abstract was published before the European Society for Medical Oncology's (ESMO) congress.
The OSIRAM-1 Phase 2 trial evaluated Tagrisso (osimertinib) plus ramucirumab (Osi+Ram) versus osimertinib (Osi) alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer.
Between November 2018 and April 2020, 122 patients were enrolled.
With a median follow-up of ...